IL23R and psoriasis: The IL-23/Th17 axis (IL23R, STAT3) is already targeted in IBD by monoclonal antibodies such as ustekinumab (IL-12/23p40) and risankizumab (IL-23p19), initially developed for psoriasis and later repurposed for Crohn’s disease and ulcerative colitis [58,59].